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Background: The transition from an-
drogen-dependent to androgen-inde-
pendent prostate cancer is not fully
understood but appears to involve
multiple genetic changes. We have
identified a gene, GC79, that is more
highly expressed in androgen-depen-
dent LNCaP-FGC human prostate can-
cer cells than in androgen-independent
LNCaP-LNO human prostate cancer
cells. Physiologic levels (0.1 nM) of an-
drogens repress expression of GC79
messenger RNA (mRNA) in LNCaP-
FGC cells. To determine the role of
GC79, we cloned its complementary
DNA (cDNA) and functionally charac-
terized its product. Methods: The dif-
ferentially expressed GC79 gene was
cloned from human prostate cDNA li-
braries, sequenced, and transfected
into mammalian cells to study its func-
tion. Expression of GC79 was analyzed
in various adult and fetal human tis-
sues and in prostate glands of castrated
rats. The association of GC79 expres-
sion and apoptosis was investigated in
COS-1 and LNCaP cells transfected
with GC79 cDNA. All statistical tests
are two-sided. Results: Sequence analy-
sis indicates that GC79 encodes a large,
complex, multitype zinc-finger protein,
containing nine C2H2-type zinc-finger
domains, a cysteine-rich region, and a
GATA C4-type zinc-finger domain.
Castration-induced androgen with-
drawal increased the expression of
GC79 mRNA in the regressing rat ven-
tral prostate, suggesting that the ex-
pression of GC79 mRNA is associated
with the process of apoptotic cell death
in the rat ventral prostate. Transfection
and induction of GC79 cDNA in both
COS-1 and LNCaP prostate cancer
cells led to an apoptotic index that was
eightfold higher (P<.001, two-sided
Student’s t test) than that observed in
uninduced transfected cells. Conclu-
sions: We have cloned an androgen-
repressible gene, GC79, that is poten-
tially involved in apoptosis. This
finding may have implications for the
development of androgen-independent
prostate cancer and, ultimately, for the
treatment of prostate cancer. [J Natl
Cancer Inst 2000;92:1414–21]
Prostate cancer is the second leading
cause of cancer-related deaths and the
most commonly diagnosed cancer in el-
derly men in the Western world (1). An-
drogens play a pivotal role in normal
prostate development and differentiation
(2). Initially, prostate cancer is androgen
dependent and can be treated by blocking
endogenous androgen production by cas-
tration or androgen action with antiandro-
gen therapy (3). Castration can trigger
apoptotic cell death in the rat ventral pros-
tate (4) and in a human prostate cancer
xenograft (5). Apoptosis is a physiologic
process of programmed cell death that
may be actively induced by chemicals or
genetic factors (6) or passively induced
by withdrawal of growth factors or hor-
mones (4,5). Androgen withdrawal in-
duces apoptosis in most androgen-
dependent prostate cancer cells. However,
androgen-independent prostate cancer
cells are refractory to apoptosis and can
be considered to be apoptosis resistant. It
has been reported (7) that the emergence
of androgen-independent cells and subse-
quently the generation of apoptosis-
resistant cells are associated with the ex-
pression of the apoptosis-resistant gene
bcl-2. Androgen-independent cells can
still be induced to undergo apoptosis by
certain compounds or by transfection of
complementary DNAs (cDNAs) encoding
proteins, such as p53 or p21 (8), illustrat-
ing that most factors of the apoptotic cas-
cade are still functional in these resistant
cells. However, apoptosis in androgen-
independent cells is not induced by andro-
gen withdrawal because proteins (such as
bcl-2) that suppress apoptosis may inhibit
apoptosis in these cells. Genes expressed
during castration-induced apoptosis of the
prostate include testosterone-repressed
prostate message-2 [TRPM-2 (9,10)],
transforming growth factor- (11), pros-
tate apoptosis response-4 (12), and c-fos,
c-myc, and the 70-kd heat-shock protein
(13).
The mechanism of prostate cancer pro-
gression and subsequent development of
hormone-refractory prostate cancer is not
fully understood (14,15). Cancer progres-
sion from a hormone-dependent state to a
hormone-independent state seems to be
caused by a cascade of genetic changes,
reflected by activation of oncogenes and/
or inactivation of tumor suppressor genes
(16,17). Comparison of androgen-
dependent and androgen-independent
prostate cancer tissues showed very simi-
lar losses and gains of chromosomes. This
finding suggests that the majority of chro-
mosomal changes occurred during the
growth of androgen-dependent prostate
cancer (18). It seems that subtle but es-
sential genetic differences are more likely
involved in the transition to growth of an-
drogen-independent prostate cancer (18–
20). As a first step toward determining the
molecular mechanism(s) underlying the
progression toward hormone-refractory
disease, we identified these genetic differ-
ences. By use of well-defined model sys-
tems, we cloned and subsequently char-
acterized genes involved in this transition
to determine their role in androgen-
independent prostate cancer development.
We have used differential-display, re-
verse transcription–polymerase chain re-
action (RT–PCR) analysis of human pros-
tate cancer LNCaP sublines that are
androgen dependent and androgen inde-
pendent (21,22) to clone several differen-
tially expressed cDNAs, and thus we have
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identified several genes (23–25). One of
these cDNAs was novel and derived from
a gene designated GC79, which is ex-
pressed more highly in androgen-
dependent prostate cancer cells than in
androgen-independent prostate cancer
cells. Physiologic levels (0.1 nM) of an-
drogens repress expression of GC79 mes-
senger RNA (mRNA) in LNCaP-FGC
cells (22). To determine the role of GC79
in prostate cancer cells, we have cloned




The LNCaP-FGC and LNCaP-LNO cell lines
were used to identify GC79 (21–23). The LNCaP-
FGC cell line is identical to the LNCaP cell line
provided by the American Type Culture Collection
(Manassas, VA). LNCaP-FGC cells were main-
tained at 37 °C in a humidified incubator with an
atmosphere of 5% CO2−95% air and cultured in
RPMI-1640 medium supplemented with penicillin
(200 IU/mL), streptomycin (200 g/mL), and 7.5%
fetal calf serum. LNCaP-LNO cells originate from
cultures of an early passage of the parental LNCaP
cells and grow under the same conditions as the
LNCaP-FGC cells, except that the medium con-
tained 5% fetal calf serum depleted of steroids by
treatment with dextran-coated charcoal (0.1% dex-
tran and 1% charcoal), as described previously
(22,23).
To study the effects of androgen and antian-
drogen, we used the nonmetabolizable synthetic
androgen R1881, 17-hydroxy-17-methyl-4,9,11-
estratrien-3-one (New England Nuclear, Boston,
MA), and the nonsteroidal antiandrogen bicalu-
tamide, (RS)-N-(4-cyan-3-[trifluormethyl]phenyl)-3-
(4-fluorphenylsulfonyl)-2-hydroxy-2-methylpro-
panamid (Zeneca Pharmaceuticals, Macclesfield,
U.K.). LNCaP-FGC cells were grown in 80-cm2 cul-
ture flasks until 80% confluent. Before hormones
were added, medium containing fetal calf serum was
exchanged for medium containing fetal calf serum
treated with dextran-coated charcoal for 18–24
hours. R1881 (0.1 nM) alone or R1881 (0.1 nM)
with 1 M bicalutamide was then added to the cells.
At various times, medium was discarded, and cells
were snap-frozen at −80 °C until isolation of total
RNA.
For transfection studies, COS-1 or LNCaP pros-
tate cancer cells were grown in six-well plates until
50% confluent. An ecdysone-inducible mammalian
expression system (Invitrogen Corp., San Diego,
CA) was used to study GC79 expression. The full-
length GC79 cDNA was isolated from pBS79FL by
digestion with BamHI and EcoRI and cloned into
pIND, digested with BamHI and EcoRI. We se-
quenced the resulting plasmid pINDGC79 to verify
that it carried the GC79 sequence and then used this
plasmid for transfection studies. Transfections were
performed with the Fugene 6 reagent (Boehringer
Mannheim GmbH, Mannheim, Germany). Briefly, a
total of 2 g containing pINDGC79, pVgRXR, and
pEGFP-C1 (1 : 1 : 1) was incubated for 15 minutes at
room temperature with 100 L of diluted Fugene 6
reagent (3 L of Fugene 6 reagent preincubated with
97 L of RPMI-1640 medium for 5 minutes at room
temperature). The mixture was added to cells for
18–24 hours. Expression of GC79 was induced by
addition of muristerone A (final concentration  1
M; Invitrogen Corp.) for 18–24 hours. To detect
apoptotic cells, we stained nuclei in situ with a mix-
ture of Hoechst 33342 (final concentration  1 g/
mL) and propidium iodide (final concentration 
3.5 g/mL) (Molecular Probes Inc., Eugene, OR)
for 15–30 minutes and then viewed the nuclei with a
fluorescent microscope (Zeiss, Jena, Germany).
Morphologic Analysis of Apoptosis
To determine the fraction of apoptotic cells, we
counted 300 transfected cells by fluorescent micros-
copy at a magnification of x40. Only the transfected
cells are green because of constitutively expressed
green fluorescent protein. Briefly, COS-1 or LNCaP
cells were cotransfected with pINDGC79 (a plasmid
that carries multiple ecdysone response elements in
its promoter), pVgRXR (a plasmid that carries genes
for constitutively expressed ecdysone and the reti-
noid X receptor), and pEGFP-C1 (a plasmid that
carries a gene for constitutively expressed green
fluorescent protein, to identify transfected cells).
When muristerone A (an ecdysone analogue) is
added to the transfected cells, formation of ecdy-
sone–retinoid X receptor heterodimers occurs, and
the dimers subsequently bind to the ecdysone re-
sponse elements of pINDGC79, leading to the ex-
pression of GC79. Apoptotic cells are identified by
the presence of blue, condensed, fragmented nuclei.
The presence of apoptotic cells was also established
independently by use of annexin V coupled to fluo-
rescein isothiocyanate, which specifically binds to
membranes of apoptotic cells. In the absence of mu-
risterone A, cultures of transfected cells have sub-
stantially fewer apoptotic cells. In addition, when
cultures of cells transfected with pIND (the empty
plasmid), pVgRXR, and pEGFP-C1 were treated
with muristerone A, no apoptotic cells were de-
tected. The apoptotic index was determined by di-
viding the number of apoptotic transfected cells by
the total number of normal transfected cells, and the
result was expressed as a percentage ([number of
apoptotic green cells/number of normal green cells]
× 100).
Animal Experiments
Young adult male RP Wistar rats (250–300 g)
were obtained from Harlan Sprague-Dawley, Inc.
(Indianapolis, IN), and were maintained under nor-
mal laboratory conditions. Animal protocols were in
accord with the guidelines of the experimental ani-
mal health care center (EDC or Experimenteel Dier
Centrum) of the Erasmus University Rotterdam, The
Netherlands. Castration was performed by the ab-
dominal route in rats under ether anesthesia; testes,
fat pads, and epididymides were removed. The rats
were killed by decapitation while under CO2 anes-
thesia 0, 4, and 7 days after castration. The ventral
prostate glands were removed rapidly, snap-frozen
in liquid nitrogen, and stored at −80 °C until isola-
tion of total RNA.
Molecular Cloning
The 255-base-pair (bp) GC79 fragment (nucleo-
tides 3237–3492) obtained from the differential dis-
play RT–PCR analysis (22) was 32P labeled and
used as probe. Screening a XbaI-(dT)15 [an oli-
go(dT) primer including an XbaI restriction site]-
primed human prostate 5-STRETCH cDNA library
DR2 (Clontech Laboratories, Inc., Palo Alto, CA)
yielded three positive clones. The largest clone
(pDR2-79) had an insert of 1570 bp (nucleotides
2106–3676) that contained zinc-finger domains 6
and 7, a GATA-type zinc-finger domain, and the
255-bp sequence and ended with a XbaI restriction
endonuclease site. Because of this XbaI site, another
round of screening was performed with the 1570-bp
fragment as probe on an oligo(dT)+ random-primed
human prostate 5-STRETCH cDNA library gt10
(Clontech Laboratories, Inc.). This second-round
screening yielded six positive clones, and the largest
overlapping clones (pCR2-79.5.3, nucleotides
1038–2173; pCR2-79.3-4.3, nucleotides 3192–
4541; and pCR2-79.3, nucleotides 3389–5507) con-
tained the sequence from zinc-finger domain 2 to a
putative poly(A) tail (nucleotides 1038–5507). The
most 5 clone (pCR2-79.5.3, nucleotides 1038–
2173) was used as probe for a third-round screening
on gt10, and this screening yielded 14 positive
clones. One of these clones (pCR2B, nucleotides
1–2800) contains a putative ATG start codon, har-
boring a Kozak consensus sequence (26).
To facilitate cloning of full-length GC79 for fur-
ther studies, we introduced a BamHI site upstream of
the start codon (nucleotides 174–179) by using the
primer 5-CGATGGATCCACAGATATGGTC-
CGG-3 (where the BamHI site is underlined). PCR
was performed with this primer, a GC79 primer
(79t8r, nucleotides 806–829, 5-GTCTGGGTTGT-
CATTCACCAG-3), and pCR2B as template. The
PCR product was subcloned by use of the TA (i.e.,
thymidine adenosine) cloning procedure (Invitrogen
Corp.) and sequenced as follows: Briefly, the GC79
fragment was isolated by digestion with BamHI and
Bsu36I (nucleotides 174–615) and ligated into
pCR2B, which had been digested with BamHI (at a
site located upstream of the introduced BamHI site)
and Bsu36I. The resulting plasmid was sequenced
and designated pCR2E. When BamHI and ApaI
were used, a larger part of GC79 was isolated
(nucleotides 174–2779) from pCR2E. The sequence
that included the stop codon was isolated from the
most 3 clone (pCR2-79.3, nucleotides 3389–
5507). The GC79 fragment was isolated after diges-
tion with ApaI (nucleotides 2776–2782) and EcoRI
(nucleotides 4079–4085), whose restriction sites are
located downstream of the stop codon (nucleotides
4029–4031). Both fragments were ligated to pBlue-
script KS(+) (Stratagene, La Jolla, CA) that had
been digested with BamHI and EcoRI. The resulting
plasmid now harbored the full-length open reading
frame of GC79 (nucleotides 174–4085), as verified
by sequencing, and was named pBS79FL.
Northern Blot Analysis
For cell lines, total RNA was isolated by the urea/
lithium chloride method as described previously
(22). For rat ventral prostate glands, total RNA was
isolated with a guanidine isothiocyanate-based mi-
cro-RNA isolation kit (Stratagene). Total RNA was
subjected to electrophoresis in a 1.5% denatured
agarose gel, blotted onto a nylon membrane (Hy-
bond N; Amersham, Buckinghamshire, U.K.), and
fixed to the membrane by use of a Stratalinker UV
crosslinker (Stratagene). The 255-bp GC79 cDNA
probe was purified from agarose gels with the
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QIAEXII gel extraction kit (Qiagen, Chatsworth,
CA) and labeled with deoxyadenosine 5-[-
32P]triphosphate (Amersham) by random primed la-
beling. The rat TRPM-2 probe was used to confirm
apoptosis (8). Hybridization was performed over-
night at 42 °C (2–5 × 106 cpm/mL), and the blots
were washed with 2× standard saline citrate for 2
minutes, followed by a washing in 2× standard sa-
line citrate−0.25% sodium dodecyl sulfate for at
least 5 minutes. Radioactive material was monitored
with a Geiger-Mu¨ller counter. The blots were ex-
posed to x-ray film (Hyperfilm MP; Amersham) at
−80 °C with intensifying screens for at least one night.
Dot Blot Analysis
A human dot blot (Master blot; Clontech Labora-
tories, Inc.) was used that contained poly(A)+ RNA
(range  89–514 ng/dot) isolated from 50 different
normal human tissues obtained from individuals
who died of trauma. The amounts of RNA on the
blot were normalized against eight different house-
keeping genes. Hybridization with a 32P-labeled
255-bp GC79 probe was performed according to the
manufacturer’s instructions. The blot was exposed
to an x-ray film at −80 °C with intensifying screens
for at least one night or analyzed alternatively for
several hours at room temperature with a Phospho-
rImager (Molecular Dynamics, Sunnyvale, CA).
Chromosomal Localization
The 255-bp GC79 fragment (22) was 32P labeled
and used as a probe to screen a genomic human PAC
(P1 phage artificial chromosome) library on gridded
filters (Genome Systems, St. Louis, MO). Hybrid-
ization was performed according to the manufactur-
er’s instructions. Genomic DNA was isolated from
positive PAC clones according to the manufacturer’s
protocol and used for fluorescence in situ hybridiza-
tion analysis (24). Briefly, genomic DNA was la-
beled with digoxigenin by use of a Dig-Nick kit
(Boehringer Mannheim GmbH). Chromosome
preparations were made from phytohemagglutinin-
stimulated lymphocytes. The hybridization signal
was visualized by incubation with anti-Dig-FITC
(i.e., digoxigenin coupled to fluorescein isothiocya-
nate; Boehringer Mannheim GmbH). The slides
were mounted in a Vecta Shield (Vector Laborato-
ries, Inc., Burlingame, CA) containing 4,6-
diamino-2-phenylindole (Sigma Chemical Co., St.
Louis, MO). Analysis was performed with a Leica
DM-RXA microscope equipped with a PowerGene
image analysis system (Perceptive Scientific Instru-
ments, Inc., Chester, U.K.).
Statistical Analysis
Data on apoptotic cell death are presented as the
means and 95% confidence intervals. All statistical
analyses were performed with two-tailed Student’s t
tests in the SPSS version 8.0 computer software
package (SPSS, Inc., Chicago, IL). Data were con-
sidered to be statistically significantly different at
P<.001.
RESULTS
The overlapping GC79 cDNA clones
yield a cDNA of 5507 bp. A homology
search in the EMBL/GenBank databases
was performed with the use of the
BLAST server (27). GC79 was found to
be novel and encoded a protein of 1281
amino acids with a calculated molecular
mass of approximately 141 kd. GC79 has
nine C2H2-type zinc-finger motifs, a cys-
teine-rich region, and a C4 GATA-type
zinc-finger motif (Fig. 1).
Previously, we have shown that GC79
mRNA expression is repressed by andro-
gen in a time-dependent and concentra-
tion-dependent fashion (22). Fig. 2, A,
shows that androgen (0.1 nM R1881) re-
pressed GC79 mRNA levels after 4 hours,
whereas simultaneous addition of 1 M
bicalutamide, an antiandrogen, reversed
the repression (Fig. 2, B). Bicalutamide
alone did not alter GC79 mRNA expres-
sion under androgen-deprived culture
conditions (data not shown). These results
strongly implicate the androgen receptor
in the androgen regulation of GC79.
GC79 mRNA was ubiquitously ex-
pressed in adult tissues (Fig. 2, C). In fetal
tissues, expression was lower than that in
the corresponding adult tissues.
Castration-induced androgen with-
drawal shows that, in rat ventral prostate,
the levels of GC79 mRNA were increased
at 4 days and decreased at 7 days after
castration (Fig. 2, D). During this period,
apoptotic cell death is assumed to be in-
duced, as illustrated by a similar pattern
of mRNA from the apoptotic-associated
gene TRPM-2 (Fig. 2, E). These results
show that increased GC79 mRNA is di-
rectly associated with induction of apop-
tosis of the rat ventral prostate.
GC79 was cloned in an inducible vec-
tor and transfected in both COS-1 cells
(Fig. 3, A–E) and LNCaP cells (Fig. 3,
F–J). In Fig. 3, A, blue intact nuclei and
blue condensed fragmented nuclei are
shown, representing apoptotic cells. In
Fig. 3, B, expression of green fluorescent
protein, cotransfected with GC79 in the
same cells, is shown. These results dem-
onstrate that expression of GC79 is asso-
ciated with apoptosis. Cultures of nonin-
duced transfected cells have fewer
apoptotic cells (Fig. 3, C and D). Fig. 3,
E, illustrates that cells induced to express
GC79 had an eightfold greater apoptotic
index (two-sided, P<.001) than uninduced
cells. Fig. 3, F–J, shows similar results for
LNCaP cells.
The chromosomal location of the
GC79 gene was 8q23–24.1 (Fig. 4).
DISCUSSION
Molecular cloning analysis showed
that GC79 is a complex and multitype
zinc-finger protein. Many proteins con-
taining zinc-finger structures have been
reported to be involved in oncogenesis
and growth regulation (28–31). Because
GC79 has two or three different types of
zinc-finger structures, we speculate that
GC79 is a unique novel transcription fac-
tor. With the use of different probes lo-
cated throughout the full-length GC79
cDNA, a single hybridization signal of
approximately 6 kilobases was observed
on northern blots. This finding demon-
strates that GC79 is not a fusion product.
To our knowledge, a protein that contains
both C2H2 and GATA types of zinc-finger
domains has not been described before.
Thus, GC79 might be the first member of
a novel class of zinc-finger transcription
factors. The GATA domain of GC79 has
77% homology with the C-terminal
GATA domain of the superfamily of
GATA transcription factors, GATA-1 to
GATA-6 (29,30). These transcription fac-
tors bind DNA sequences with the (A/
T)GATA(A/G) motif. All six vertebrate
members of the GATA family contain
two C4 zinc-finger domains, whereas
GC79 only has a single C4 zinc-finger do-
main. The two C4 zinc-finger domains of
the GATA family are 50% homologous
with each other (29,30). The GATA tran-
scription factors are involved in cell pro-
liferation, differentiation, and regulation
of genes (29,30), which indicates that
GC79 may also be involved in these ac-
tivities. For example, the GATA domain
of GC79 could bind to the DNA consen-
sus sequence (A/T)GATA(A/G) and thus
regulate gene expression.
We have shown previously (22) that
the expression of GC79 mRNA in
LNCaP-FGC cells is repressed by andro-
gen (0.1 nM R1881) in a time-dependent
and concentration-dependent manner. Re-
pression was relatively fast (after 4 hours)
and was observed at a physiologic con-
centration (0.1 nM R1881). Fig. 2 shows
that an antiandrogen (bicalutamide) is
able to reverse the effect of androgen
(R1881) and indicates that the androgen
repression activity of GC79 is mediated
by the androgen receptor. It is not known
whether GC79 binds to the androgen re-
ceptor. It is interesting to note that, when
a steroid (estrogen) binds to its receptor
(estrogen receptor), the activity of a
GATA-binding protein (GATA-1) is re-
pressed (32). This estrogen-mediated
repression could be reversed by an antis-
teroid (4-hydroxytamoxifen), which sug-
gests involvement of the estrogen recep-
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Fig. 1. Sequence of GC79. Panel A: nucleotide and amino acid sequence.
Numbering of nucleotide sequences is on the left. The 255-base-pair probe from
the differential display reverse transcription–polymerase chain reaction (22) is in
boldface type. Polyadenylation sites are underlined. Numbering of amino acid
sequences is on the right. Nine C2H2-type zinc-finger motifs (Cys–X2–Cys–
X12–14–His–X3–5–His), originally found in transcription factor TFIIIA of Xeno-
pus laevis (28), are in boldface type. A cysteine-rich region (positions 564–595),
which may represent a novel type of zinc-cluster motif (Cys–X2–Cys–X4–Cys–
X14–Cys–X4–Cys–X2–Cys), is in italic type. A C4-type zinc-finger motif (Cys–
XN–Cys–X17–Cys–NA–Cys; positions 893–933), originally found in the GATA
family of DNA-binding transcription factors (29,30), is in boldface italic type.
Basic regions representing putative nuclear localization signals are underlined.
The GenBank accession number is AF264784. Panel B: alignment of C2H2
zinc-finger domains. Panel C: comparison of GC79 C4 GATA-type zinc-finger
domain with C-terminal zinc-finger domains of human GATA-1 to GATA-4 and
GATA-6 (46–50) and with chicken GATA-5 (34). The degree of homology
between the GATA C4 zinc-finger domain of GC79 and the GATA family is 50%
to the N-terminal end and 77% to the C-terminal C4 zinc-finger domain (29,30).
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tor. Furthermore, protein–protein binding
between the estrogen receptor and
GATA-1 in vitro was reported (32).
Whether these observations are applicable
to GC79 and the androgen receptor is
speculative as yet. Alternatively, andro-
gen repression activity of GC79 involving
the androgen receptor is indicative of the
presence of a negative hormonal respon-
sive element in the GC79 promoter. To
our knowledge, the only negative hor-
monal responsive element recognized
by the androgen receptor is in maspin, a
tumor-suppressing serine protease inhibi-
tor (33). Molecular cloning, sequencing,
and functional analysis of the promoter
region of GC79 could identify regulatory
elements involved in GC79 gene expres-
sion.
The tissue distribution of GC79
mRNA expression was studied with an
RNA dot blot containing RNAs from
multiple human tissues. Expression of
GC79 was found to be high in the pros-
tate, testis, ovary, kidney, lung, and mam-
mary gland. Lower levels of expression
were found in the liver, colon, heart,
uterus, and brain. It is interesting that
in fetal tissues (kidney, lung, liver, heart,
and brain) GC79 expression was lower
than that in the corresponding adult
tissues. This result could suggest that
during adulthood GC79 might be in-
volved in growth suppression of these
tissues. GATA-4, GATA-5, and GATA-6
have been described in developing heart
and gut (34), and GATA-2 has been re-
ported to have a vital role during urogeni-
tal development (35). Recently, it has
been reported that GATA transcription
factors are involved in gonadal develop-
ment. For example, GATA-4 and
GATA-6 are expressed and hormonally
regulated in mouse ovary (36) and in
mouse testis (37). Furthermore, GATA-4
is expressed during early gonadal devel-
opment and sexual differentiation of
mouse gonads (38). GATA-4 is a potent
activator of the promoter for Mu¨llerian
inhibiting substance (38). Potential
GATA-binding sites have also been iden-
Fig. 2. Analysis of GC79 messenger RNA (mRNA) expression. Panels A and B:
regulation in androgen-dependent human LNCaP-FGC prostate cancer cells by
R1881. LNCaP-FGC prostate cancer cells were cultured with 0.1 nM R1881 in
the absence or presence of 1 M bicalutamide. Total RNA was isolated at
various times, and 20 g was loaded per lane of a 1.5% denatured agarose gel,
subjected to electrophoresis, blotted onto nylon filters, and hybridized with the
32P-labeled 255-base-pair GC79 probe. Each lane contains an equal amount of
total RNA, as measured by absorbance at 260 nm and ethidium bromide staining.
In panel A, 0.1 nM R1881 was used. In panel B, 0.1 nM R1881 with 1 M
bicalutamide was used. Lanes 1  0 hour, lanes 2  1 hour, lanes 3  2 hours,
lanes 4  4 hours, lanes 5  6 hours, and lanes 6  8 hours. Panel C:
expression of GC79 in different human tissues. A dot blot containing poly(A)+
RNA (range  89–514 ng/dot) from 50 different normalized human tissues was
hybridized with the 32P-labeled 255-base-pair GC79 probe. Row A is as follows:
1  whole brain, 2  amygdala, 3  caudate nucleus, 4  cerebellum, 5 
cerebral cortex, 6  frontal lobe, 7  hippocampus, and 8  medulla oblon-
gata. Row B is as follows: 1  occipital lobe, 2  putamen, 3  substantia
nigra, 4  temporal lobe, 5  thalamus, 6  subthalamic nucleus, and 7 
spinal cord. Row C is as follows: 1  heart, 2  aorta, 3  skeletal muscle,
4  colon, 5  bladder, 6  uterus, 7  prostate, and 8  stomach. Row D
is as follows: 1  testis, 2  ovary, 3  pancreas, 4  pituitary gland, 5 
adrenal gland, 6  thyroid gland, 7  salivary gland, and 8  mammary gland.
Row E is as follows: 1  kidney, 2  liver, 3  small intestine, 4  spleen,
5 thymus, 6 peripheral leukocyte, 7 lymph node, and 8 bone marrow.
Row F is as follows: 1  appendix, 2  lung, 3  trachea, and 4  placenta.
Row G is as follows: 1  fetal brain, 2  fetal heart, 3  fetal kidney, 4 
fetal liver, 5  fetal spleen, 6  fetal thymus, and 7  fetal lung. Row H is as
follows: 1  yeast total RNA (100 ng), 2  yeast transfer RNA (100 ng), 3 
Escherichia coli ribosomal RNA (100 ng), 4  E. coli DNA (100 ng), 5 
poly[r(A)] (100 ng), 6  human Cot 1 DNA (genomic DNA enriched for
repetitive sequences) (100 ng), 7  human genomic DNA (100 ng), and 8 
human genomic DNA (500 ng). Panels D–F: expression of GC79 in the rat
ventral prostate gland undergoing castration-induced apoptosis. Adult male RP
Wistar rats were castrated, and total RNA was isolated from the regressing
ventral prostate glands at various times as indicated. With the use of a 1.5%
denatured agarose gel, 20 g of total RNA was loaded per lane, subjected to
electrophoresis, blotted onto nylon filters, and hybridized with the 32P-labeled
255-base-pair GC79 probe or a probe for the apoptosis-associated rat TRPM-2
gene (9). It should be noted that rat GC79 mRNA has the same size as human
GC79 mRNA (data not shown). Each lane contains an equal amount of total
RNA as measured by absorbance at 260 nm and ethidium bromide staining.
Panel D shows GC79. Panel E shows TRPM-2. Panel F shows ethidium bro-
mide staining of total RNA. Lanes 1  normal intact ventral prostate gland,
lanes 2  4-day castration ventral prostate gland, and lanes 3  7-day castra-
tion ventral prostate gland.
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tified in the promoter of Mu¨llerian inhib-
iting substance type II receptor (39).
GATA-1 and GATA-4 can activate the
promoter of the gonadal gene inhibin 
(40). Because GC79 seems to be differ-
entially expressed in normal and fetal tis-
sues, GC79 might be involved in urogeni-
tal or gonadal development.
During androgen ablation therapy
(e.g., antiandrogen treatment or castra-
tion), when androgens are repressed, it is
hypothesized that apoptosis occurs in
both the normal and the malignant human
prostates as it does in the normal rat ven-
tral prostate (4,5). Because we observed
that expression of GC79 is high when an-
drogen levels are low in LNCaP-FGC
cells, we hypothesize that GC79 might be
involved in the arrest of cell growth and/
or apoptotic cell death. So that we could
test this hypothesis in vivo, rats were cas-
trated and GC79 mRNA expression in the
regressing rat ventral prostate gland was
measured. GC79 mRNA increased 4 days
after castration and remained high until 7
days after castration. The rat apoptotic
marker TRPM-2 (9) has a similar expres-
sion pattern, indicating that apoptotic cell
death of the rat ventral prostate gland has
been induced. These results demonstrate
that GC79 mRNA expression coincides
Fig. 3. GC79 expression is associated
with apoptosis in COS-1 (panels A–E)
and LNCaP prostate cancer (panels F–J)
cells. GC79 complementary DNA was li-
gated in the ecdysone-inducible expres-
sion vector and transiently cotransfected
with ecdysone receptor, retinoic acid X
receptor, and green fluorescent protein.
GC79 expression was induced by addi-
tion of muristerone A, an ecdysone ana-
logue. Panels A, C, F, and H: Hoechst
33342–propidium iodide staining of nu-
clei. Panels B, D, G, and I: GC79 ex-
pression, colocalized with green fluores-
cent protein. After transfection, cells
were treated with (A, B, F, and G) or
without (C, D, H, and I) 1 M murister-
one A for 18–24 hours to induce GC79
expression. Panels E and J: apoptotic in-
dex ([number of apoptotic transfected
cells/number of normal transfected cells]
× 100). The percentage of apoptotic cells
was determined by scoring 300 trans-
fected cells. Values are expressed as the
means and 95% confidence intervals of
three independent experiments carried
out in triplicate. *P<.001 as assessed by
two-tailed Student’s t test. Scale bars 
20 m.
Fig. 4. Chromosomal localization of
GC79. Southern blot analysis using
the 32P-labeled 255-base-pair GC79
probe on LNCaP-FGC genomic
DNA, digested with HindIII, EcoRI,
or BamHI, demonstrated that GC79
is encoded by a single copy gene
(data not shown). Screening of a hu-
man genomic PAC (P1 phage artifi-
cial chromosome) library yielded
three positive clones (62P9, 136H8,
and 212M23). Genomic DNA was
isolated from PAC clone 212M23,
verified by polymerase chain reaction
analysis, and used as probe. Panel A:
in situ hybridization of digoxigenin-
labeled GC79 PAC clone 212M23 on
a metaphase spread of human chromosomes derived from phytohemagglutinin-stimulated lymphocytes.
Specific labeling was observed at 8q23–24.1 (arrowheads). Panel B: a representative idiogram showing the
8q23–24.1 region. Images were obtained with a Leica DM-RXA microscope equipped with a PowerGene
analysis system.
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with apoptotic cell death in the rat ventral
prostate gland and suggests that GC79 is
involved in apoptosis of normal andro-
gen-dependent prostate epithelial cells,
present in the rat ventral prostate gland.
Whether the GC79 protein is present in
the secretory epithelium of the involuting
rat ventral prostate is under investigation.
Because the function of endogenous
GC79 is still unknown, we are currently
studying whether inhibition of GC79 pre-
vents castration-induced apoptosis in the
rat ventral prostate. The involvement of
GC79 in the apoptotic process of the
mammalian cell lines COS-1 and LNCaP
was shown in transient transfection stud-
ies with the use of the ecdysone-inducible
mammalian expression system. Induction
of GC79 expression with muristerone A
in GC79-transfected cells resulted in the
appearance of many apoptotic cells with
condensed fragmented nuclei. This result
indicates that GC79 belongs to a class of
androgen-repressed genes that are associ-
ated with or involved in apoptosis (9–13).
Transforming growth factor- (11) and
prostate apoptosis response-4 (12) have
been reported to be expressed during cas-
tration-induced regression of the prostate.
The c-myc gene, which can be repressed
by androgen (13), has also been reported
to be involved in apoptosis (41,42). It is
interesting that c-myc is localized to hu-
man chromosome 8q24, whereas we
mapped GC79 to human chromosome
8q23–24.1. Whether there is a link be-
tween expression of GC79 and c-myc is
an intriguing question. It would be inter-
esting to determine whether GC79 and c-
myc share similar or different apoptotic
pathways. It has been reported that el-
evated levels of c-myc were observed in
prostate carcinomas (43,44) and that am-
plification of c-myc was present only in a
subset of tumors with an 8q gain (44).
Recently, it was reported (45) that an 8q
gain (as measured by c-myc) is associated
with progression of prostate carcinomas.
Identification and functional characteriza-
tion of genes on the 8q arm are important
and will extend our current knowledge of
the involvement of chromosome 8q in
prostate cancer progression.
In conclusion, we have cloned GC79, a
gene with potential tumor growth-
suppressing activity that is associated
with apoptosis. GC79 is a zinc-finger pro-
tein and can be repressed by physiologic
concentrations of androgen in optimally
growing androgen-dependent prostate
cancer cells. Androgen withdrawal leads
to an increase in GC79 and subsequent
cell growth arrest, followed by apoptosis.
GC79 is a gene that is potentially in-
volved in prostate cancer apoptosis and
may be important in the treatment of pros-
tate cancer.
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